Why there is opportunity in biotech and the names to watch

Kevin Mahn, Hennion and Walsh chief investment officer, joins ‘The Exchange’ to discuss the names he’s favoring in the pharma sector.

Click here to watch the video on CNBC.

Disclosure: Hennion & Walsh Asset Management currently has allocations within its managed money program and Hennion & Walsh currently has allocations within certain SmartTrust® Unit Investment Trusts (UITs) consistent with several of the portfolios management ideas for consideration discussed during this interview.